Market Overview:
The global integrin alpha V market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of metabolic disorders, ophthalmology, respiratory, and infectious diseases. Additionally, the increasing demand for novel therapeutics for various indications is also contributing to the growth of this market. Based on type, MK-0429 is expected to account for a major share of the global integrin alpha V market during the forecast period. This can be attributed to its high efficacy and safety profile as compared to other available therapies.
Product Definition:
An integrin is a type of receptor protein that interacts with the extracellular matrix, which is a collection of proteins and other molecules that surrounds cells. There are many different types of integrins, but one example is alpha V beta 3. This integrin binds to certain molecules in the extracellular matrix called fibronectin. It helps cells attach to and move around in their environment.
MK-0429:
MK-0429 is a small molecule, which acts as an inhibitor of integrin alpha v (ITGAV). It has been found to be effective in the treatment of multiple myeloma and lymphomas. Currently, it is under clinical investigation for the treatment of these diseases. The drug has also shown promising results in phase II clinical trials for solid tumors; however, failed phase I studies have raised concerns regarding its potential therapeutic value.
C-16Y:
C-16Y is a nonapeptide, naturally occurring growth factor for human cells. It is used as an immunogen to raise antibodies against the protein in the blood. The presence of C-16Y antigen in the blood indicates that a person has been exposed to influenza virus recently. This test can be performed on any type of patient suffering from flu like symptoms and also on people who have just recovered from flu like illness.
Application Insights:
Metabolic disorders segment dominated the global integrin alpha V market in terms of revenue in 2017. The growing prevalence of metabolic disorders, especially diabetes, is anticipated to be a key factor driving the segment growth over the forecast period. According to WHO, currently approximately 9% of population globally suffers from diabetes and this number is expected to reach around 20% by 2050. Moreover, according to Diabetes Australia more than 1 million people are diagnosed with diabetes every year and around 300000 Australians have prediabetes symptoms which means they are at high risk for developing full blown type 2 diabetes soon. This surge in incidence has created a huge demand for innovative drugs that can cure or at least help treat this disease which is likely to boost product demand during the forecast period.
The others application segment includes cancer.
Regional Analysis:
North America dominated the global integrin alpha V market in terms of revenue share in 2016. The region is expected to maintain its dominance during the forecast period due to increasing R&D activities and high healthcare expenditure. Moreover, approval and commercialization of products in this region are also responsible for maintaining a higher revenue share for the global market.
Asia Pacific is anticipated to grow at a lucrative rate over the forecast period owing to rising disposable income coupled with growing awareness regarding integrin alpha V deficiency disease management options available worldwide. In addition, increasing number of clinical trials being conducted on various platforms such as animal models or humanized mice will further drive growth over this period.
Growth Factors:
- Increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and arthritis is expected to drive the demand for integrin alpha V inhibitors over the forecast period.
- Growing geriatric population is also anticipated to boost the market growth owing to increasing incidence of age-related disorders such as cancer and arthritis.
- Rising awareness about benefits offered by integrin alpha V inhibitors in treatment of various chronic diseases is projected to propel the demand for these drugs in coming years.
- Technological advancements in drug discovery and development are likely to provide lucrative opportunities for market players over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Integrin Alpha V Market Research Report
By Type
MK-0429, C-16Y, 264-RAD, AC-301, Others
By Application
Metabolic Disorders, Ophthalmology, Respiratory, Infectious Disease, Others
By Companies
Biogen Inc, BioMAS Ltd, Factor Therapeutics Ltd, MedImmune LLC, Merck & Co Inc, Merck KGaA, Morphic Therapeutic Inc, SciFluor Life Sciences LLC, Vascular Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Integrin Alpha V Market Report Segments:
The global Integrin Alpha V market is segmented on the basis of:
Types
MK-0429, C-16Y, 264-RAD, AC-301, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Metabolic Disorders, Ophthalmology, Respiratory, Infectious Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen Inc
- BioMAS Ltd
- Factor Therapeutics Ltd
- MedImmune LLC
- Merck & Co Inc
- Merck KGaA
- Morphic Therapeutic Inc
- SciFluor Life Sciences LLC
- Vascular Pharmaceuticals Inc
Highlights of The Integrin Alpha V Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- MK-0429
- C-16Y
- 264-RAD
- AC-301
- Others
- By Application:
- Metabolic Disorders
- Ophthalmology
- Respiratory
- Infectious Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Integrin Alpha V Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Integrin alpha V is a protein that helps cells attach to other cells. It is also involved in the process of cell migration.
Some of the major players in the integrin alpha v market are Biogen Inc, BioMAS Ltd, Factor Therapeutics Ltd, MedImmune LLC, Merck & Co Inc, Merck KGaA, Morphic Therapeutic Inc, SciFluor Life Sciences LLC, Vascular Pharmaceuticals Inc.
The integrin alpha v market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Integrin Alpha V Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Integrin Alpha V Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Integrin Alpha V Market - Supply Chain
4.5. Global Integrin Alpha V Market Forecast
4.5.1. Integrin Alpha V Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Integrin Alpha V Market Size (000 Units) and Y-o-Y Growth
4.5.3. Integrin Alpha V Market Absolute $ Opportunity
5. Global Integrin Alpha V Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Integrin Alpha V Market Size and Volume Forecast by Type
5.3.1. MK-0429
5.3.2. C-16Y
5.3.3. 264-RAD
5.3.4. AC-301
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Integrin Alpha V Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Integrin Alpha V Market Size and Volume Forecast by Application
6.3.1. Metabolic Disorders
6.3.2. Ophthalmology
6.3.3. Respiratory
6.3.4. Infectious Disease
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Integrin Alpha V Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Integrin Alpha V Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Integrin Alpha V Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Integrin Alpha V Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Integrin Alpha V Demand Share Forecast, 2019-2026
9. North America Integrin Alpha V Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Integrin Alpha V Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Integrin Alpha V Market Size and Volume Forecast by Application
9.4.1. Metabolic Disorders
9.4.2. Ophthalmology
9.4.3. Respiratory
9.4.4. Infectious Disease
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Integrin Alpha V Market Size and Volume Forecast by Type
9.7.1. MK-0429
9.7.2. C-16Y
9.7.3. 264-RAD
9.7.4. AC-301
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Integrin Alpha V Demand Share Forecast, 2019-2026
10. Latin America Integrin Alpha V Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Integrin Alpha V Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Integrin Alpha V Market Size and Volume Forecast by Application
10.4.1. Metabolic Disorders
10.4.2. Ophthalmology
10.4.3. Respiratory
10.4.4. Infectious Disease
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Integrin Alpha V Market Size and Volume Forecast by Type
10.7.1. MK-0429
10.7.2. C-16Y
10.7.3. 264-RAD
10.7.4. AC-301
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Integrin Alpha V Demand Share Forecast, 2019-2026
11. Europe Integrin Alpha V Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Integrin Alpha V Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Integrin Alpha V Market Size and Volume Forecast by Application
11.4.1. Metabolic Disorders
11.4.2. Ophthalmology
11.4.3. Respiratory
11.4.4. Infectious Disease
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Integrin Alpha V Market Size and Volume Forecast by Type
11.7.1. MK-0429
11.7.2. C-16Y
11.7.3. 264-RAD
11.7.4. AC-301
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
1.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Integrin Alpha V Demand Share, 2019-2026
12. Asia Pacific Integrin Alpha V Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Integrin Alpha V Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Integrin Alpha V Market Size and Volume Forecast by Application
12.4.1. Metabolic Disorders
12.4.2. Ophthalmology
12.4.3. Respiratory
12.4.4. Infectious Disease
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Integrin Alpha V Market Size and Volume Forecast by Type
12.7.1. MK-0429
12.7.2. C-16Y
12.7.3. 264-RAD
12.7.4. AC-301
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Integrin Alpha V Demand Share, 2019-2026
13. Middle East & Africa Integrin Alpha V Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Integrin Alpha V Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Integrin Alpha V Market Size and Volume Forecast by Application
13.4.1. Metabolic Disorders
13.4.2. Ophthalmology
13.4.3. Respiratory
13.4.4. Infectious Disease
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Integrin Alpha V Market Size and Volume Forecast by Type
13.7.1. MK-0429
13.7.2. C-16Y
13.7.3. 264-RAD
13.7.4. AC-301
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Integrin Alpha V Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Integrin Alpha V Market: Market Share Analysis
14.2. Integrin Alpha V Distributors and Customers
14.3. Integrin Alpha V Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Biogen Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. BioMAS Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Factor Therapeutics Ltd
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. MedImmune LLC
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck & Co Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck KGaA
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Morphic Therapeutic Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. SciFluor Life Sciences LLC
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Vascular Pharmaceuticals Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
